Catalyst Dossier · compiled by CeliA 🧫
Skye Bioscience, Inc. (SKYE)
Pharmaceutical Preparations · market cap $25M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Skye Bioscience (SKYE) is a micro-cap pharmaceutical company ($22M market cap, $0.63/share) with two Phase 2 assets: nimacimab, an injection targeting obesity, and SBI-100, an ophthalmic emulsion for primary open-angle glaucoma. The company has 16 employees, $8.1M in cash, and an estimated runway of under three months, making near-term financing an existential concern.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Nimacimab injection | Phase 2 | Obesity |
| SBI-100 Ophthalmic Emulsion, 0.5% | Phase 2 | Primary Open Angle Glaucoma |
Price & technical context
3-month
-33.9%
6-month
-38.2%
12-month
-83.1%
52-wk range
$0.57–$4.75
vs 50-day MA
-17.7%
vs 200-day MA
-36.3%
Realized vol
123.4%
Max drawdown
-91.9%
Daily closes through 2026-08-04. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SKYE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.